IPX066
GSK announces bepirovirsen’s ‘functional cure’ data to treat chronic hepatitis B
Over 240 million people worldwide live with chronic hepatitis B
GSK signs agreement with Protas to streamline clinical trials
The new three-year agreement builds on an existing two-year relationship
Sumitomo Pharma’s stem cell therapy for Parkinson’s given limited approval in Japan
The company has been given manufacturing and marketing authorisation for the therapy
Annovis partners with NeuroRPM on new AI platform to track Parkinson’s symptoms
The platform will passively collect data to understand treatment responses in everyday life
GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension
PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide
GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults
RSV affects approximately 64 million people around the world each year
GSK’s Nucala approved by MHRA for uncontrolled COPD
Symptoms of COPD include breathlessness, persistent cough and frequent chest infections
GSK’s Blenrep approved by FDA for multiple myeloma
Approval supported by positive results from phase 3 trial
Mission Therapeutics advances Parkinson’s disease candidate
The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK
PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s
The US-based company develops light-based therapies for neurodegenerative conditions
GSK and Hengrui enter multi-programme collaboration agreement worth $12bn
The deal includes a PDE3/4 inhibitor in clinical development for COPD
GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma
More than 50,000 cases of the blood cancer are diagnosed in Europe each year